VIKING THERAPEUTICS INC (VKTX)

US92686J1060 - Common Stock

51.63  +0.1 (+0.19%)

Premarket: 53.12 +1.49 (+2.89%)

Fundamental Rating

3

VKTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While VKTX has a great health rating, there are worries on its profitability. VKTX is valued expensive and it does not seem to be growing.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

VKTX had negative earnings in the past year.
In the past year VKTX has reported a negative cash flow from operations.
In the past 5 years VKTX always reported negative net income.
In the past 5 years VKTX always reported negative operating cash flow.

1.2 Ratios

VKTX's Return On Assets of -10.57% is amongst the best of the industry. VKTX outperforms 88.06% of its industry peers.
VKTX has a Return On Equity of -10.88%. This is amongst the best in the industry. VKTX outperforms 90.73% of its industry peers.
Industry RankSector Rank
ROA -10.57%
ROE -10.88%
ROIC N/A
ROA(3y)-30.09%
ROA(5y)-22.95%
ROE(3y)-33.1%
ROE(5y)-24.95%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VKTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

VKTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VKTX has more shares outstanding
VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

VKTX has an Altman-Z score of 130.59. This indicates that VKTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VKTX (130.59) is better than 99.82% of its industry peers.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 130.59
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 36.47 indicates that VKTX has no problem at all paying its short term obligations.
The Current ratio of VKTX (36.47) is better than 98.93% of its industry peers.
A Quick Ratio of 36.47 indicates that VKTX has no problem at all paying its short term obligations.
VKTX has a better Quick ratio (36.47) than 98.93% of its industry peers.
Industry RankSector Rank
Current Ratio 36.47
Quick Ratio 36.47

More info and screens

1

3. Growth

3.1 Past

The earnings per share for VKTX have decreased by 0.00% in the last year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 34.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.98%
EPS Next 2Y-29.46%
EPS Next 3Y-24.87%
EPS Next 5Y34.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
Also next year VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

VKTX's earnings are expected to decrease with -24.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.46%
EPS Next 3Y-24.87%

More info and screens

0

5. Dividend

5.1 Amount

VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIKING THERAPEUTICS INC

NASDAQ:VKTX (11/21/2024, 8:00:04 PM)

Premarket: 53.12 +1.49 (+2.89%)

51.63

+0.1 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.75B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.57%
ROE -10.88%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 36.47
Quick Ratio 36.47
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.98%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y